Drebber Uta, Baldus Stephan E, Nolden Britt, Grass Guido, Bollschweiler Elfriede, Dienes Hans P, Hölscher Arnulf H, Mönig Stefan P
Institute of Pathology, University of Cologne, Cologne, Germany.
Oncol Rep. 2008 Jun;19(6):1477-83.
The purpose of this study was to clarify the relationship of the immunohistochemical expression of c-met, p53 and p21 with clinicopathological parameters and prognosis in gastric carcinomas. We analyzed specimens from 114 gastric cancer patients (median age 64 years, range: 33-86) who underwent gastrectomy with lymphadenectomy. Specimens were categorized according to the tumor differentiation, based on UICC, WHO, Laurén, Ming and Goseki classifications. Specimens were examined immunohistochemically with antibodies against c-met, p53 and p21. The expression was evaluated semiquantitatively and correlated with the clinicopathological parameters. The c-met staining pattern was positive in 73.7%. P53 and p21 were positive in 86.8 and 67.5%, respectively. No significant correlation between c-met or p21 expression and the clinicopathological parameters was seen. A significant increase of p53 expression was observed in stage pT3 and -4. The overexpression of c-met and p53 was significantly associated with a poor prognosis in the univariate survival analysis. In the multivariate analysis this impact was maintained for c-met. P21 proved to be a significant prognostic factor in the multivariate analysis. Our data suggest that the overexpression of c-met and p21 may represent independent prognostic factors in gastric carcinoma.
本研究的目的是阐明c-met、p53和p21的免疫组化表达与胃癌临床病理参数及预后的关系。我们分析了114例行胃癌根治术加淋巴结清扫术的胃癌患者（中位年龄64岁，范围：33 - 86岁）的标本。根据国际抗癌联盟（UICC）、世界卫生组织（WHO）、劳伦（Laurén）、明（Ming）和五木（Goseki）分类法，标本按肿瘤分化程度进行分类。用抗c-met、p53和p21的抗体对标本进行免疫组化检查。对表达进行半定量评估，并与临床病理参数进行相关性分析。c-met染色阳性率为73.7%。p53和p21的阳性率分别为86.8%和67.5%。未观察到c-met或p21表达与临床病理参数之间存在显著相关性。在pT3和pT4期观察到p53表达显著增加。在单因素生存分析中，c-met和p53的过表达与预后不良显著相关。在多因素分析中，c-met的这种影响依然存在。在多因素分析中，p21被证明是一个显著的预后因素。我们的数据表明，c-met和p21的过表达可能代表胃癌的独立预后因素。
